Overview
Dr. Ardalan's clinical interests are in juvenile myositis, lupus, and scleroderma and he is co-director of the Duke Children's Myositis Center. He also co-leads the Duke Pediatric Lupus Clinic. Dr. Ardalan's research interests encompass health-related quality of life, patient-reported outcomes, mental health, psychological stress, adverse childhood experiences, cardiovascular health and outcomes research, psychometrics, and qualitative/mixed methods research. His most recent work, funded by the Rheumatology Research Foundation Investigator Award, focuses on the relationships between psychological stress, inflammation, and cardiovascular health in juvenile lupus and dermatomyositis.
Current Appointments & Affiliations
Assistant Professor of Pediatrics
·
2021 - Present
Pediatrics, Rheumatology,
Pediatrics
Recent Publications
Congruence Between Child Self-Reported and Caregiver-Proxy-Reported Health-Related Quality of Life in Children With Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus.
Journal Article J Rheumatol · January 15, 2026 OBJECTIVE: To explore congruence between child self-reported and caregiver-proxy-reported health-related quality of life (HRQOL) over time in juvenile idiopathic arthritis (JIA) and childhood-onset systemic lupus erythematosus (cSLE), and to identify facto ... Full text Link to item CiteRemission and low disease activity definitions in adult idiopathic inflammatory myopathies: A narrative review by myositis clinical trials consortium (MCTC).
Journal Article Autoimmun Rev · September 24, 2025 Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of rare systemic autoimmune rheumatic diseases. Despite advances in treatment, the definition of remission and low disease activity (LDA) in IIM remains inconsistent and lacks consensus and ... Full text Link to item CiteApproach to Janus kinase inhibition for juvenile dermatomyositis among CARRA and PReS providers.
Journal Article Rheumatology (Oxford) · August 1, 2025 OBJECTIVES: Janus kinase inhibition (JAKi) has been proposed as a treatment for idiopathic inflammatory myopathies to target increased interferon signalling. Predominantly retrospective reports have demonstrated effectiveness of JAKi in refractory JDM. How ... Full text Link to item CiteRecent Grants
Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2025 - 2030A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy or A
Clinical TrialPrincipal Investigator · Awarded by Cabaletta Bio, Inc. · 2025 - 2028Using Bioengineered Human Muscle to Develop Treatments for Juvenile Dermatomyositis
ResearchCollaborator · Awarded by Hartwell Foundation · 2025 - 2028View All Grants
Education, Training & Certifications
University of Virginia, School of Medicine ·
2009
M.D.